ALBANY — Albany Molecular Research Inc. announced Monday it had changed its name and announced Tuesday it had acquired a California biopharmaceutical firm.
AMRI is now Curia. Chairman and CEO John Ratliff said Monday that “Our new name reflects the assembled deep expertise of our people, the breadth of our products, services and solutions, and our relentless determination to help customers advance from curiosity to cure.”
Curia has entered a definitive agreement to acquire Integrity Bio, a formulation and fill-finish organization. Curia said Integrity’s biologic capabilities are complementary with Curia’s existing businesses. Terms of the deal were not disclosed; it is expected to close later this quarter.
Ratliff said the deal would strengthen Curia’s market position and give it a greater presence on the West Coast.
Curia is a contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries. It is based in Albany and has 3,100 employees at 21 locations across the United States, Europe and Asia.